Announcement no. 4/2007
To the Copenhagen Stock Exchange Copenhagen, February
20th, 2007
Curalogic presents ragweed data at the AAAAI meeting
Resume: Curalogic presents data from phase II study at the annual meeting in the
”American Academy of Allergy, Asthma and Immunology”, San Diego, USA.
Curalogic is pleased to announce that Dr. Creticos will present the findings of
his clinical phase II study with Curalogic's ragweed pollen extract at the 2007
American Academy of Allergy, Asthma, and Immunology meeting in San Diego on
Saturday, February 24th, 2007. The result of this study shows that ragweed
pollen extract manufactured by Curalogic's new producer can be used in the
further development and marketing of the ragweed product. Dr. Creticos is
Medical Director at the Johns Hopkins Asthma and Allergy Center, Baltimore,
Maryland.
The study was finalized in the late summer 2006, and top line results were
released September 4th, 2006. Data from the AAAAI meeting can be found in a
poster on Curalogic's homepage (www.curalogic.com) from Monday February 26th,
2007.
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO, Phone +45 33 11 41 01, mobile +45 20 70 55 37
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the Copenhagen Stock
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the
treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.
Curalogic has a broad and mature pipeline with a product for treatment of
ragweed allergy ready for Phase III, products for treatment of grass allergy and
cat allergy in Phase II and a product for treatment of house dust mite allergy
preparing for clinical trials.
This announcement contains forward-looking statements regarding the company's
future financial development and performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the company's knowledge, are reasonable at
this time, but may prove to be erroneous in the future.
